GARIVULIMAB
UNII CSJ7UEQ4D9

Substance Identification & Data

This profile provides standardized clinical and technical data for Garivulimab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) CSJ7UEQ4D9.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2342597-81-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

CSJ7UEQ4D9

CAS Registry Number

2342597-81-1

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

GARIVULIMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C155654

National Cancer Institute reference terminology for clinical and research data.

INN ID

11451

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Garivulimab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

GARIVULIMAB

Common Names & Synonyms

GARIVULIMAB [INN]

IMMUNOGLOBULIN G1 (233-PROLINE,234-ALANINE,235-ALANINE,DE-237-GLYCINE,329-ALANINE), ANTI-(HUMAN PROGRAMMED CELL DEATH LIGAND 1) (HUMAN-MUS MUSCULUS MONOCLONAL BGB-A333 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL BGB-A333 .KAPPA.-CHAIN, DIMER

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CD274 (PROGRAMMED DEATH LIGAND 1, PDL1, PD-L1, B7 HOMOLOG 1, B7H1)), HUMANIZED MONOCLONAL ANTIBODY